Lokon Pharma

3:00 PM - 3:15 PM (EDT), Wednesday, June 7, 2023 ・ Session Room 104A
Lokon Pharma is a privately owned, Swedish biotech company developing immunostimulatory gene therapy for cancer with a focus on pancreatic cancer. The therapeutic platform stems from Uppsala University in Sweden. Our clinical lead, LOAd703, is an adenovirus serotype 5/35 encoding our designed TMZ-CD40L and wild type 4-1BBL that together drives initiation of anti-tumor immunity. LOAd703 is currently evaluated in three trials in both Europe and the US. In pancreatic cancer, LOAd703 combined with standard of care chemotherapy (arm 1) has shown promising results with a 55% overall response rate in the highest dose cohorts. Another arm combining LOAd703, chemotherapy and anti-PDL1 (atezolizumab) is soon completed.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
LOAd703 - delolimogene mupadenorepvec
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Lokon Pharma